Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

   Completed · Phase 2, Phase 3 · COVID-19

   NCT04427501 · Eli Lilly and Company · 2 U.S. investigators

   $77,958research payments

2. CAR- PRISM (PRecision Intervention Smoldering Myeloma)

   Active, not recruiting · Phase 2 · Multiple Myeloma

   NCT05767359 · Menarini Silicon Biosystems, Inc. · 1 U.S. investigator

   $77,841research payments

3. Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

   Completed · Phase 3 · Autism Spectrum Disorder

   NCT05439616 · AbbVie Inc. · 11 U.S. investigators

   $76,858research payments

4. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

   Recruiting · Phase 2 · Agitation

   NCT06808984 · E.r. Squibb & Sons, L.l.c. · 40 U.S. investigators

   $76,549research payments

5. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

   Recruiting · Phase 3 · Bipolar-I Disorder With Mania or Mania With Mixed Features

   NCT06951698 · E.r. Squibb & Sons, L.l.c. · 18 U.S. investigators

   $76,463research payments

6. Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

   Completed · Phase 1, Phase 2 · Influenza Immunization

   NCT05553301 · Sanofi Pasteur Inc. · 2 U.S. investigators

   $76,032research payments

7. Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

   Active, not recruiting · Phase 2 · Scleroderma, Diffuse

   NCT02682511 · Cumberland Pharmaceuticals, Inc. · 8 U.S. investigators

   $76,004research payments

8. A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin

   Completed · Phase 4 · Crepey Skin

   NCT07398989 · Galderma Laboratories, L.P. · 2 U.S. investigators

   $75,975research payments

9. A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

   Terminated · Phase 4 · Multiple Myeloma

   NCT03173092 · Takeda Pharmaceuticals U.S.A., Inc. · 13 U.S. investigators

   $74,500research payments

10. Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility

    Completed · Not applicable · Lung Diseases

    NCT03641677 · United Therapeutics Corporation · 6 U.S. investigators

    $73,478research payments

11. A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

    Active, not recruiting · Phase 2 · Multiple Myeloma

    NCT03314181 · AbbVie Inc. · 6 U.S. investigators

    $72,667research payments

12. Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension

    Not yet recruiting · Early phase 1 · Pulmonary Hypertension

    NCT07116681 · United Therapeutics Corporation · 1 U.S. investigator

    $72,543research payments

13. A Comparative Analysis of Two Hyaluronic Acid Fillers for Nasolabial Fold Correction

    Completed · Not applicable · Wrinkle

    NCT06351293 · Galderma Laboratories, L.P. · 1 U.S. investigator

    $72,400research payments

14. IL13 Signaling in Allergic Asthma

    Completed · Asthma, Allergic

    NCT05478824 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $72,199research payments

15. A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

    Active, not recruiting · Phase 3 · Renal Cell Carcinoma

    NCT03873402 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

    $71,675research payments

16. A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

    Completed · Phase 1 · Diabetes Mellitus, Type 2

    NCT02942914 · Eli Lilly and Company · 10 U.S. investigators

    $71,552research payments

17. Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

    Completed · Phase 2 · Myeloid Leukemia, Chronic, Chronic Phase

    NCT02467270 · Takeda Pharmaceuticals U.S.A., Inc. · 5 U.S. investigators

    $71,390research payments

18. Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

    Completed · Phase 2 · Acne Vulgaris

    NCT05080764 · Biofrontera Inc. · 5 U.S. investigators

    $71,064research payments

19. Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

    Recruiting · Phase 1, Phase 2 · Multiple Myeloma

    NCT06105554 · Menarini Silicon Biosystems, Inc. · 1 U.S. investigator

    $70,764research payments

20. Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

    Status unknown · Phase 4 · Septic Shock

    NCT06122987 · La Jolla Pharmaceutical Company · 0 U.S. investigators

    $70,600research payments

21. Post-Market Clinical Study on a Modular SI Joint Fusion System

    Active, not recruiting · Sacroiliitis

    NCT05916092 · Foundation Fusion Solutions, LLC · 10 U.S. investigators

    $70,395research payments

22. Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects

    Completed · Phase 1 · Healthy

    NCT04570267 · Csl Behring · 6 U.S. investigators

    $70,173research payments

23. A Clinical Registry to Demonstrate the Safety and Performance of Teleflex Vascular Access Devices

    Recruiting · Vascular Access Device

    NCT06604039 · Teleflex LLC · 3 U.S. investigators

    $70,086research payments

24. Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

    Completed · Phase 3 · Stroke

    NCT00781391 · Daiichi Sankyo Inc. · 1 U.S. investigator

    $70,000research payments

25. A Global Study of the PETAL Consortium

    Recruiting · T-Cell and NK-Cell Neoplasm

    NCT06067347 · Daiichi Sankyo Inc. · 0 U.S. investigators

    $70,000research payments

26. REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

    Terminated · Phase 1 · Severe Aplastic Anemia (SAA)

    NCT04409080 · Regeneron Pharmaceuticals, Inc. · 2 U.S. investigators

    $69,866research payments

27. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

    Completed · Phase 3 · Overweight

    NCT04184622 · Eli Lilly and Company · 9 U.S. investigators

    $69,547research payments

28. A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

    Completed · Phase 4 · Fabry's Disease

    NCT06019728 · Sanofi US Services Inc. · 5 U.S. investigators

    $69,533research payments

29. Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

    Completed · Phase 3 · Hematological Malignancies

    NCT04260698 · Gamida Cell Inc. · 3 U.S. investigators

    $69,178research payments

30. Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

    Completed · Phase 3 · Leukemia, Myeloid, Acute

    NCT01757535 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

    $68,780research payments

31. Streamlined Resin Y90 Radiation Segmentectomy for Small HCC

    Active, not recruiting · Hepatocellular Carcinoma (HCC)

    NCT06618300 · Sirtex Medical Inc · 1 U.S. investigator

    $68,252research payments

32. Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion

    Recruiting · Not applicable · Left Atrial Appendage Closure

    NCT06348394 · Philips North America LLC · 1 U.S. investigator

    $68,000research payments

33. Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

    Completed · Phase 2 · Ulcerative Colitis

    NCT05570006 · AbbVie Inc. · 8 U.S. investigators

    $67,891research payments

34. A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

    Completed · Phase 3 · Type 1 Diabetes

    NCT05463744 · Eli Lilly and Company · 8 U.S. investigators

    $67,660research payments

35. Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

    Not yet recruiting · Phase 3 · Contraception

    NCT04457076 · Sebela Women's Health Inc. · 8 U.S. investigators

    $67,302research payments

36. Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)

    Completed · Phase 3 · Crohn's Disease

    NCT03279081 · Takeda Pharmaceuticals U.S.A., Inc. · 7 U.S. investigators

    $67,259research payments

37. Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

    Completed · Phase 1 · Locally Advanced and Metastatic Solid Tumors

    NCT04047862 · Beone Medicines USA, Inc. · 9 U.S. investigators

    $66,868research payments

38. A Study of LY3502970 in Participants With Impaired and Normal Liver Function

    Completed · Phase 1 · Healthy

    NCT05882032 · Eli Lilly and Company · 4 U.S. investigators

    $66,801research payments

39. Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

    Completed · Phase 2 · Duchenne Muscular Dystrophy Cardiomyopathy

    NCT03340675 · Cumberland Pharmaceuticals, Inc. · 6 U.S. investigators

    $66,609research payments

40. ProACT Post-Approval Study

    Recruiting · Not applicable · Stress Urinary Incontinence

    NCT03767595 · Uromedica, Incorporated · 5 U.S. investigators

    $66,486research payments

41. Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

    Completed · Phase 3 · Functional Constipation

    NCT04026113 · AbbVie Inc. · 9 U.S. investigators

    $66,448research payments

42. The PASTDUe Nutrition Ecosystem Project (PASTDUe)

    Active, not recruiting · Phase 4 · Diet, Healthy

    NCT05127109 · Baxter Healthcare · 1 U.S. investigator

    $66,269research payments

43. A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

    Completed · Phase 3 · Von Willebrand Disease (VWD)

    NCT03879135 · Takeda Pharmaceuticals U.S.A., Inc. · 6 U.S. investigators

    $66,261research payments

44. A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

    Active, not recruiting · Phase 2, Phase 3 · Prostate Cancer

    NCT03706365 · Eli Lilly and Company · 13 U.S. investigators

    $66,049research payments

45. A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib

    Completed · Phase 1 · Healthy Adults

    NCT05868356 · Mirati Therapeutics, Inc. · 1 U.S. investigator

    $65,414research payments

46. A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

    Completed · Phase 3 · Urinary Bladder Neoplasms

    NCT03661320 · E.r. Squibb & Sons, L.l.c. · 7 U.S. investigators

    $65,215research payments

47. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

    Recruiting · Phase 1, Phase 2 · Multiple Myeloma

    NCT06892522 · AbbVie Inc. · 2 U.S. investigators

    $64,900research payments

48. A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

    Completed · Phase 1, Phase 2 · Advanced Solid Tumors

    NCT04393298 · UCB SA · 3 U.S. investigators

    $64,892research payments

49. MEASuRE: Metreleptin Effectiveness And Safety Registry

    Recruiting · Generalised Lipodystrophy

    NCT02325674 · Chiesi USA, Inc. · 11 U.S. investigators

    $64,280research payments

50. A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

    Active, not recruiting · Phase 3 · Clear Cell Renal Cell Carcinoma

    NCT04810078 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $64,255research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.